Interview: MedPacto Sees Robust Prospects For ‘Best-In-Class’ ALK5 Inhibitor

MedPacto is preparing for a critical Phase II US study with its potentially best-in-class ALK5 inhibitor, a potential rival to a Lilly molecule and that will be central to the South Korean bioventure’s long-term ambitions to become a global player.

South Korean bioventure MedPacto Inc. has reached a pivotal stage in the development of its novel anticancer drug candidate TEW-7197, a novel oral ALK5 inhibitor that will serve as the foothold for what it sees as its best-in-class pipeline assets.

The company has already received the green light from the US FDA to start a Phase II study with the oral small molecule for the treatment of myelodysplastic syndromes (MDS),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

23 May 2025

• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

23 May 2025

• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

23 May 2025

• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

22 May 2025

• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.